Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | GMMG-HD4 and MM5: bortezomib vs. lenalidomide for myeloma maintenance

Elias Mai • 15 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Lenalidomide
GMMG-MM5 HOVON-65/GMMG-HD4

Elias Mai, MD, from the University Hospital Heidelberg, Heidelberg, Germany, talks about the GMMG-HD4 (NCT03617731) and MM5 (EudraCT no. 2010-019173-16) trials of bortezomib versus lenalidomide maintenance therapy for myeloma. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Elias Mai

Isa-RVd induction therapy in patients with newly diagnosed multiple myeloma: the GMMG-HD7 trial 4:22
Isa-RVd induction therapy in patients with newly diagnosed multiple myeloma: the GMMG-HD7 trial
Elias Mai • 9 Dec 2024
Predicting and preventing early relapse in patients with newly diagnosed multiple myeloma 2:48
Predicting and preventing early relapse in patients with newly diagnosed multiple myeloma
Elias Mai • 9 Dec 2024
Advantages and applications of mass spectrometry in multiple myeloma 1:03
Advantages and applications of mass spectrometry in multiple myeloma
Elias Mai • 25 Apr 2023
The role of daratumumab in combination with lenalidomide as maintenance therapy in NDMM post-autoSCT 1:31
The role of daratumumab in combination with lenalidomide as maintenance therapy in NDMM post-autoSCT
Elias Mai • 25 Apr 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals